TP53 and breast cancer: In this regard, Olivier’s group demonstrated that 4-hydroxy-tamoxifen (OHT), a selective estrogen receptor modulator (SERM), suppresses cell proliferation more effectively in breast cancer cell lines bearing wild-type p53 compared to cells with mutated p53.